VMD Medicines update - April 2026

See the VMD’s Product Information Database for more information on each of these products. There may be a delay before formal documentation is available for some Northern Ireland products, from the European Medicines Agency.

The timing of the product being placed on the market is an issue for the marketing authorisation holder.

New marketing authorisations 
Novel products
Scovella 15 mg/ml Oral Solution for Horses is the first veterinary medicinal product containing velagliflozin to be authorised in GB for use in horses.  The product is specifically authorised for the treatment of hyperinsulinaemia in insulin-dysregulated horses and ponies not responsive to changes in husbandry and exercise regimen.

TABLE 1: New marketing authorisations in April 2026

Changes to authorisations most relevant to vets

The changes to authorisations most relevant to vets can be found below. Each product is listed, along with the authorisation holder, distribution category and details of which Summary of Product Characteristics (SPC) sections have been revised/changed.

Changes to the SPC, labels and leaflets may change how the medicines should be used.  Details can be found on the VMD’s Product Information Database (PID).

Due to ongoing assessments, there may be a delay between the point at which a new change is authorised and the updated SPC being available on the PID.  There may also be a delay between the point at which any SPC changes are authorised and implementation in the product literature. Unless you have been advised otherwise, the labelling instructions on the pack which is dispensed should be followed.

Recocam 20 mg/ml Solution for Injection for Cattle, Pigs and Horses

Bimeda Animal Health Limited       GB      POM‑V

SPC Section 3.2 added: For the relief of post-operative pain following dehorning in calves.

Section 3.4 Special warnings: Treatment of calves with the veterinary medicinal product 20 minutes before dehorning reduces postoperative pain. The veterinary medicinal product alone will not provide adequate pain relief during the dehorning procedure. To obtain adequate pain relief during surgery co-medication with an appropriate analgesic is needed.

Regumate Equine 2.2 mg/ml Oral Solution for Horses

Intervet International B.V.    GB & NI         POM-V

SPC Section 3.5 Special precautions to be taken by the person administering the veterinary medicinal product to animals: Adverse reproductive effects reported in men include decreased libido.

Acute effects after single exposure are possible, but repeated accidental exposure has the potential for more adverse effects.

This veterinary medicinal product should not be handled by:

• persons with known or suspected breast cancer or other progesterone-dependent tumours
• persons with thrombo-embolic disorders or a history of those
• persons with cerebral-vascular or coronary-artery disease
• women with vaginal bleeding of unknown cause
• persons with liver dysfunction or disease.

People with known hypersensitivity to the active substance should avoid contact with the veterinary medicinal product.

Avoid contact with skin, eyes and oral ingestion due to hand-to-mouth contact.

Personal protective equipment consisting of overalls and chemical resistant single-use gloves (e.g. nitrile gloves) should be worn when handling the veterinary medicinal product. This veterinary medicinal product can penetrate latex or other types of porous gloves and absorption through the skin may be even higher when the area is covered by an occlusive material.

Do not eat, drink or smoke while handling the product.

Wash hands after use.

In case of accidental ingestion do not induce vomiting as pulmonary damage via aspiration of oil base may occur. Seek medical advice immediately and show the package leaflet or the label to the physician.

Any equipment or surfaces that come into contact with the veterinary medicinal product should be adequately cleaned and decontaminated to prevent human exposure. Wear gloves when cleaning.

VETERELIN 0.004 mg/ml Solution for Injection for Cattle, Horses, Pigs, and Rabbits

Laboratorios Calier, S.A.     GB & NI         POM‑V

Revision of most sections of SPC including addition of information to Section 3.4 Special warnings, Section 3.5 Special precautions to be taken by the person administering the product, Section 3.7 Use during pregnancy, lactation, or lay, Section 3.9 Administration routes and dosage, and Section 4.3 Pharmacokinetics.

For more information, contact the VMD at postmaster@vmd.gov.uk